Lexeo Therapeutics Inc. Common Stock (LXEO) Stock Price, Quote & News

AI Score

Unlock

AI Score

Our AI model analyzes fundamental, technical, and statistical indicators to predict the probability of a bullish trend over the next three months.

We regularly update and refine our models to deliver the most reliable forecasts for you.

Bullish Probability	Sentiment	Score
+80%	Strong Buy	10
+75%	Buy	9
+70%	Buy	8
+60%	Buy	7
+50%	Hold	6
+45%	Hold	5
+40%	Hold	4
+35%	Sell	3
+30%	Sell	2
+20%	Strong Sell	1

Lexeo Therapeutics Inc. C... (LXEO)

AI Score

Unlock

AI Score

Bullish Probability	Sentiment	Score
+80%	Strong Buy	10
+75%	Buy	9
+70%	Buy	8
+60%	Buy	7
+50%	Hold	6
+45%	Hold	5
+40%	Hold	4
+35%	Sell	3
+30%	Sell	2
+20%	Strong Sell	1

5.63

-0.17 (-2.93%)

At close: Jan 15, 2025, 2:43 PM

undefined% (undefined)

Bid	5.6
Market Cap	186.00M
Revenue (ttm)	-
Net Income (ttm)	-
EPS (ttm)	-12.64
PE Ratio (ttm)	-0.45
Forward PE	n/a
Analyst	Buy

Ask	5.65
Volume	119,960
Avg. Volume (20D)	383,254
Open	6.00
Previous Close	5.80
Day's Range	5.45 - 6.05
52-Week Range	5.45 - 22.33
Beta	undefined

About LXEO

Lexeo Therapeutics, Inc. operates as a clinical-stage genetic medicine company that focuses on hereditary and acquired diseases. The company develops LX2006, which is an AAVrh10-based gene therapy candidate for the treatment of Friedreich's ataxia (FA) cardiomyopathy; LX2020, an AAVrh10-based gene therapy candidate for the treatment of arrhythmogenic cardiomyopathy; LX2021, a gene therapy candidate for the treatment of DSP cardiomyopathy associat...

[Show more]

Industry Biotechnology

Sector Healthcare

IPO Date Nov 3, 2023

Employees 69

Stock Exchange NASDAQ

Ticker Symbol LXEO

Website https://www.lexeotx.com

Analyst Forecast

According to 5 analyst ratings, the average rating for LXEO stock is "Buy." The 12-month stock price forecast is $24.5, which is an increase of 335.56% from the latest price.

Buy 100.00%

Hold 0.00%

Sell 0.00%

Stock Forecasts

Why Price Moved

2 months ago · Source

-0.65%

Lexeo Therapeutics shares are trading higher. Leer... Unlock content with Pro Subscription

2 months ago · Source

-16.95%

Lexeo Therapeutics shares are trading lower. The company announced interim results from its Phase 1/2 study of LX1001.

News

6 months ago · seekingalpha.com

Lexeo: Higher Dosing LX2006 Could Ignite FA Cardiomyopathy Program Further

Lexeo Therapeutics, Inc. achieved positive results across two studies using LX2006 for the treatment of patients with Friedreich's Ataxia Cardiomyopathy; Clinically meaningful improvements observed in...

6 months ago · zacks.com

Lexeo (LXEO) Down Despite Upbeat Rare Disease Gene Therapy Data

Interim data from an early-stage study shows that treatment with Lexeo's (LXEO) experimental gene therapy reduced signs of heart complications in patients with Friedreich's ataxia.

6 months ago · benzinga.com

Nasdaq Surges Over 1%; Lexeo Therapeutics Shares Plummet

U.S. stocks traded higher midway through trading, with the Nasdaq Composite rising more than 200 points on Monday.

8 months ago · zacks.com

What Makes Lexeo Therapeutics, Inc. (LXEO) a New Buy Stock

Lexeo Therapeutics, Inc. (LXEO) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).

9 months ago · seekingalpha.com

Lexeo: Targeted Alzheimer's Disease Treatment Approach Might Pay Off

Lexeo Therapeutics, Inc. has results from its phase 1/2 SUNRISE-FA study, using LX-2006 for the treatment of patients with FA cardiomyopathy, expected in mid-2024. Results from all cohorts of phase 1/...

1 year ago · investorplace.com

LXEO Stock Earnings: Lexeo Therapeutics Reported Results for Q3 2023

Lexeo Therapeutics (NASDAQ: LXEO ) just reported results for the third quarter of 2023. Lexeo Therapeutics reported earnings per share of -$12.36.

1 year ago · seekingalpha.com

U.S. IPO Weekly Recap: Biotech Lexeo Stumbles After $100 Million IPO

Two IPOs are currently scheduled for the week ahead, although some small issuers may join the calendar late. As of 11/2/2023, the Renaissance IPO Index was up 23.5% year-to-date, while the S&P 500 was...

1 year ago · marketwatch.com

Lexeo Therapeutics' stock falls 15% in trading debut after its IPO priced below range

Lexeo Therapeutics Inc.'s stock LXEO, -15.01% tumbled 15% in its trading debut on Friday, after the company's initial public offering priced below the proposed price range. The stock priced at $11, be...

1 year ago · seekingalpha.com

Lexeo Therapeutics Proposes Terms For $126 Million IPO

Lexeo Therapeutics, Inc. has filed to raise $126 million in an IPO, to support developing treatments for cardiovascular and Alzheimer's conditions. The company's lead candidate, LX2006, is in Phase 1/...

1 year ago · seekingalpha.com

Lexeo Therapeutics Starts $100 Million U.S. IPO Effort

Lexeo Therapeutics, Inc. has filed for a $100 million IPO to develop treatments for cardiovascular and Alzheimer's conditions, although the final figure may differ. The company's lead candidate, LX200...